Adagene Inc.
ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-huā¦ read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.96
Price+15.98%
$0.27
1Y
Price
Market Cap
$73.868m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$511.080k
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$49.349m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$1.40
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$50.524m
$89.268m
Assets$38.745m
Liabilities$18.494m
DebtDebt to Assets
20.7%
-0.4x
Debt to EBITDAFree Cash Flow
-$36.428m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company